Innovative Combination Therapy Offers Hope for Advanced Lung Cancer Patients

2025-06-20 transformation

Seoul, Friday, 20 June 2025.
A study from Samsung Medical Center, Seoul demonstrates promising results for a savolitinib and osimertinib combo therapy, showing durable responses in hard-to-treat EGFR-mutated advanced NSCLC cases.

Breakthrough in NSCLC Treatment

In a recent clinical examination conducted at Samsung Medical Center, Seoul, the combination therapy of savolitinib and osimertinib has demonstrated substantial efficacy in patients suffering from advanced non-small cell lung cancer (NSCLC) that presents EGFR mutations along with MET overexpression. The study, encompassing the Phase 2 SAVANNAH trial, revealed an objective response rate (ORR) of 56% as assessed by investigator review, alongside a 55% ORR observed via blinded independent central review (BICR) [1].

Details of the SAVANNAH Trial

The trial notably recorded a median time to response of approximately six weeks and a median duration of response extending from 7.1 to 9.9 months according to varying review metrics. Patients partaking in the study were at least 18 years old (≥20 in Japan), presented with locally advanced or metastatic NSCLC, and had experienced progression following an initial osimertinib monotherapy [1]. Different dosing regimens were analyzed during the trial, incorporating savolitinib at doses of 300 mg once or twice daily alongside a consistent osimertinib dose of 80 mg daily [1].

Implications for Clinical Practice

The implications of these findings are profound, potentially shifting clinical protocols towards more personalized treatment regimens. This combination leverages targeting both the EGFR pathway and MET overexpression, collectively addressing common resistance issues encountered with singular therapies. Given the high rates of adverse events in the initial therapeutic approaches, the savolitinib and osimertinib duo bears the promise of a more refined and responsive treatment profile [1][5].

Future Perspectives

The trial results pave avenues for redefining NSCLC treatment norms, particularly in refining outcomes through tailored combination therapies. Such advances could significantly alter existing standard care frameworks, advocating for an approach centered on genetic specificity and molecular diagnostics in oncology. The trial further underlines the necessity for continued research aimed at expanding therapeutic boundaries, allowing for innovations that could transform oncological care paradigms worldwide [1][2].

Bronnen

cancer therapy NSCLC